Lecicarbon K Co2-Laxans Drei (Sodium Hydrogen Carbonate, Sodium Dihydrogen Phosphate)

Sodium Hydrogen Carbonate dissociates in the colon, generating an osmotic gradient that draws water from the surrounding tissues into the intestinal lumen. The added fluid softens feces, expands the lumen, and stimulates peristalsis, facilitating bowel movements.

The appropriate dose of Lecicarbon K Co2-Laxans Drei is determined by a qualified healthcare professional based on the individual’s condition, age, and response. Patients should follow the prescriber’s instructions and the product label without deviation.

Safety data for Lecicarbon K Co2-Laxans Drei in pregnancy or lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and only under medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lecicarbon K Co2-Laxans Drei uses a combination of sodium hydrogen carbonate and sodium dihydrogen phosphate to create an osmotic effect, similar to polyethylene glycol‑based preparations. Compared with PEG, it may act more rapidly but can carry a higher risk of electrolyte shifts, especially in patients with renal impairment.

Store Lecicarbon K Co2-Laxans Drei at room temperature, preferably below 25 °C. Keep the container tightly closed, protect it from moisture, direct sunlight, and excessive heat to maintain product stability.

The product is intended for rectal administration. It is typically introduced into the rectum as a suppository or enema according to the prescriber’s directions, allowing the active ingredients to act locally within the colon.

Serious risks include electrolyte imbalance (such as hypernatremia or phosphate disturbances), severe dehydration, allergic reactions that may present as rash or angioedema, and rectal bleeding. Patients should seek immediate medical attention if any of these symptoms occur.

Individuals with known hypersensitivity to sodium hydrogen carbonate, sodium dihydrogen phosphate, or any excipients should avoid the product. It is also contraindicated in patients with severe renal impairment, uncontrolled electrolyte disorders, or active rectal inflammation without medical advice.